Libret 50 mg/100 ml (IV Infusion)
Medicine Details
| Category | Details |
|---|---|
| Generic | Ranitidine hydrochloride |
| Company | Libra infusions ltd |
Indications
- Treatment of active duodenal ulcer
- Benign gastric ulcer
- Prevention of ulcer associated with non-steroidal anti-inflammatory agent
- Post operative stress ulcer
- Zollinger-Ellison Syndrome
- Gastroesophageal reflux disease (GERD)
- Gastro-intestinal haemorrhage from stress ulcer
- Recurrent haemorrhage in patients with bleeding peptic ulcer
- Before general anesthesia in patient considered to be at risk of acid aspiration particularly obstetric patients
Pharmacology
Competitively blocks histamine at H2-receptors of the gastric parietal cells, inhibits gastric acid secretion, and does not affect pepsin secretion, pentagastrin-stimulated intrinsic factor secretion or serum gastrin
Dosage & Administration
- Ranitidine Tablet & Syrup:
- Usual dosage is 150 mg twice daily for 4 to 8 weeks
- Usual dosage is 300 mg as a single daily dose at night for 4 to 8 weeks
- 150 mg twice daily for reflux oesophagitis
- 150 mg 3 times daily for Zollinger Ellison syndrome
- 150 mg twice daily for episodic dyspepsia
- Maintenance dose of 150 mg at night
- Ranitidine IV injection & IV Infusion: Dosage depends on specific condition
Interaction
Delayed absorption and increased peak serum concentration with propantheline bromide, minimal inhibition of hepatic metabolism of certain drugs, alteration of absorption of pH-dependent drugs, and reduced bioavailability with antacids
Contraindications
Hypersensitivity to Ranitidine
Side Effects
- Altered bowel habit
- Dizziness
- Rash
- Tiredness
- Reversible confusional states
- Headache
- Decreased blood counts
- Muscle or joint pain
Pregnancy & Lactation
- Pregnancy: Should only be used if considered essential
- Lactation: Caution should be exercised when administered to nursing mothers
Precautions & Warnings
Should be given in reduced dosage to patients with impaired renal and hepatic function
Use in Special Populations
Similar ulcer healing rates in elderly patients as in younger patients, and no significant difference in adverse effects
Overdose Effects
No particular problems expected following overdosage. Symptomatic and supportive therapy should be given as appropriate
Therapeutic Class
H2 receptor antagonist
Reconstitution
- Slow IV inj: Diluted to a specific concentration with appropriate solvents
- Intermittent slow IV infusion: Diluted to a specific concentration with appropriate solvents
- Continuous IV infusion: Diluted in specific solutions
- Patients with Zollinger-Ellison syndrome or other hypersecretory conditions: Should be diluted to a specific concentration with appropriate solvents
Storage Conditions
Store in a cool and dry place, protect from light